443 related articles for article (PubMed ID: 16951230)
1. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.
Holloway AJ; Diyagama DS; Opeskin K; Creaney J; Robinson BW; Lake RA; Bowtell DD
Clin Cancer Res; 2006 Sep; 12(17):5129-35. PubMed ID: 16951230
[TBL] [Abstract][Full Text] [Related]
2. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
4. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
[TBL] [Abstract][Full Text] [Related]
6. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic role of claudins in serous effusions.
Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions.
Davidson B; Stavnes HT; Risberg B; Nesland JM; Wohlschlaeger J; Yang Y; Shih IeM; Wang TL
Hum Pathol; 2012 May; 43(5):684-94. PubMed ID: 21937081
[TBL] [Abstract][Full Text] [Related]
10. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.
Mezger J; Lamerz R; Permanetter W
J Thorac Cardiovasc Surg; 1990 Dec; 100(6):860-6. PubMed ID: 2147220
[TBL] [Abstract][Full Text] [Related]
12. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
13. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of malignant and reactive cells from serous effusions: image and texture analysis study.
García-Bonafé M; Moragas A
Anal Cell Pathol; 1996 Nov; 12(2):85-98. PubMed ID: 8986293
[TBL] [Abstract][Full Text] [Related]
15. Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells.
Mohr S; Bottin MC; Lannes B; Neuville A; Bellocq JP; Keith G; Rihn BH
Biochimie; 2004 Jan; 86(1):13-9. PubMed ID: 14987796
[TBL] [Abstract][Full Text] [Related]
16. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
17. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
Brock MV; Hooker CM; Yung R; Guo M; Han Y; Ames SE; Chang D; Yang SC; Mason D; Sussman M; Baylin SB; Herman JG
Ann Thorac Surg; 2005 Oct; 80(4):1241-7. PubMed ID: 16181847
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic analysis of effusions from malignant mesothelioma. A diagnostic adjunct to cytology.
Granados R; Cibas ES; Fletcher JA
Acta Cytol; 1994; 38(5):711-7. PubMed ID: 8091903
[TBL] [Abstract][Full Text] [Related]
19. Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer.
Jiang B; Wu GP; Zhao YJ; Wang SC
Diagn Cytopathol; 2008 Dec; 36(12):849-54. PubMed ID: 18855882
[TBL] [Abstract][Full Text] [Related]
20. Young investigator challenge: MicroRNA-21/MicroRNA-126 profiling as a novel tool for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Cappellesso R; Nicolè L; Caroccia B; Guzzardo V; Ventura L; Fassan M; Fassina A
Cancer Cytopathol; 2016 Jan; 124(1):28-37. PubMed ID: 26765063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]